Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study [Corrigendum]
Hashimoto S, Ikeuchi H, Murata S, Kitawaki T, Ikeda K, Banerji D. Int J Chron Obstruct Pulmon Dis. 2016;11:2543–2551.
On page 2547, Figure 5, x-axis, the dose mentioned in the label for IND should have read “150 μg od” instead of “110 μg od” and the dose for GLY should have read “50 μg od” instead of “110 μg od”.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]